Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder - 23/08/22
Doi : 10.1016/j.ajog.2022.05.041
Max Jordan Nguemeni Tiako, MD, MS 
Department of Internal Medicine, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02134
Harvard Medical School, Boston, MA
Urban Health Lab, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Center for Emergency Care and Policy Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, Philadelphia, PA
Angelica Meinhofer, PhD
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, Philadelphia, PA
Weill Cornell School of Medicine, New York, NY
Ari Friedman, MD, PhD
Center for Emergency Care and Policy Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Leonard Davis Institute, Wharton School of Management, University of Pennsylvania, Philadelphia, PA
Eugenia C. South, MD, MS
Urban Health Lab, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Center for Emergency Care and Policy Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Leonard Davis Institute, Wharton School of Management, University of Pennsylvania, Philadelphia, PA
Rachel L. Epstein, MD
Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA
Zachary F. Meisel, MD, MPH, MSHP
Center for Emergency Care and Policy Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, Philadelphia, PA
Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Leonard Davis Institute, Wharton School of Management, University of Pennsylvania, Philadelphia, PA
Jake R. Morgan, PhD
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, Philadelphia, PA
Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA
Le texte complet de cet article est disponible en PDF.
Plan
| The authors report no conflict of interest. |
|
| A.M. acknowledges funding from the Gerber Foundation (grant number GF192350) and the National Institute on Drug Abuse (NIDA; grant number K01DA051777). J.R.M. acknowledges funding from the NIDA (grant numbers P30DA040500, R01CE002999, and R01DA046527), and Z.F.M. acknowledges funding from the NIDA (grant number P30DA040500) and the Centers for Disease Control and Prevention (grand numbers R01CE003143 and R49CE003083). R.L.E. acknowledges funding from the Charles A. King Trust Postdoctoral Fellowship Program. |
© 2022
Elsevier Inc. Tous droits réservés.
Vol 227 - N° 3
P. 544 - septembre 2022 Retour au numéro
Article précédent
- Factors associated with SARS-CoV-2 transplacental transmission
- Alexandre J. Vivanti, Christelle Vauloup-Fellous, Guillaume Escourrou, Jonathan Rosenblatt, Jean-Marie Jouannic, Astrid Laurent-Bellue, Daniele De Luca
- Oxytocin utilization for women undergoing an induction of labor by 1 kg/m2 increase in body mass index
- Brock E. Polnaszek, Justine Reilly, Christina A. Raker, Adam K. Lewkowitz, Valery A. Danilack
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?